Crossject SA is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing.
The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

ZENEO is a pre-set in factory needle free device, it enables the easy and safe injection of a drug in only two steps, press and push into the injection site, even through clothing if necessary.

ZENEO has demonstrated through several Human Factors studies that it can be used easily and quickly even by naïve users even during an emergency situation.

There is no needle, which is a real advantage in terms of risk of laceration during injection and/or potential cross-contamination for the rescuer, or further down the disposal chain.

–  Therapeutic areas: Epilepsy, Allergy, Endocrinology, Asthma

–  Based in: Dijon (FRANCE) Affiliate in Boston (USA)

–  Employees: 51 – 200

– Created in: 2001